Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Next Previous
Trial Profile

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Enozertinib (Primary) ; Pemetrexed (Primary)
  • Indications Advanced breast cancer; Brain metastases; CNS cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus First in man; Pharmacokinetics; Registrational
  • Sponsors ORIC Pharmaceuticals

Most Recent Events

  • 13 Nov 2025 According to a ORIC Pharmaceuticals media release, the company announced a poster presentation highlighting 1L EGFR exon 20, 2L EGFR exon 20, 2L+ EGFR atypical, and 2L+ HER2 exon 20 data from a Phase 1b trial of enozertinib (ORIC-114) to be presented at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore.
  • 13 Nov 2025 According to a ORIC Pharmaceuticals media release, 2L+ dose optimization cohorts are now fully enrolled in this study.
  • 05 Aug 2025 Planned End Date changed from 1 Mar 2026 to 1 Sep 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top